- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| Di | Medicus Pharma Ltd. to Present at the Family Office Summit in Dubai, UAE | 171 | ACCESS Newswire | EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A PANEL DISCUSSIONThe Summit theme "unlocking the $1 Trillion Wealth transfer in Dubai" PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / October 7... ► Artikel lesen | |
| 29.09. | Medicus Pharma Ltd. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 29.09. | Medicus Pharma gets FDA nod for 505(b)(2) pathway in skin cancer treatment | 1 | Investing.com | ||
| 29.09. | Medicus Pharma Ltd. Receives Positive Feedback From the Food and Drug Adminstration Type C Meeting Supporting the Development of Skinject | 161 | ACCESS Newswire | The FDA agrees that the Company may follow 505(b)(2) regulatory pathway to non-invasively treat basal cell carcinoma (BCC) of the skin using dissolvable Doxorubicin-containing Microneedle arrays (D-MNA)... ► Artikel lesen | |
| 24.09. | Medicus Pharma Ltd. To Present at Brookline Capital Markets | 229 | ACCESS Newswire | The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell carcinoma of the skin (BCC) and development of Teverelix... ► Artikel lesen | |
| 18.09. | Medicus Pharma Ltd. Announces $8.0 Million Non-Dilutive Debenture Financing | 254 | ACCESS Newswire | The Company plans to use the proceeds to accelerate the development of Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and high CV... ► Artikel lesen | |
| 12.09. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | Medicus Pharma Ltd. Provides Update on United Arab Emirates SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin | 273 | ACCESS Newswire | CLEVELAND CLINIC ABU DHABI (CCAD) HAS COMMENCED RECRUITMENT IN THIS 36 PARTICIPANT STUDY PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / September 8, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus"... ► Artikel lesen | |
| 02.09. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | Medicus Pharma Ltd. Completes Acquisition of Antev Limited | 421 | Newsfile | Patrick J. Mahaffy, a veteran pharma executive and the former Chairman of Antev, appointed to Medicus Board of Directors Philadelphia, Pennsylvania--(Newsfile Corp. - September 2, 2025) - Medicus Pharma... ► Artikel lesen | |
| 22.08. | Medicus Pharma Ltd. - 8-K, Current Report | 2 | SEC Filings | ||
| 21.08. | Medicus Pharma Ltd. reports Q2 results | 1 | Seeking Alpha | ||
| 21.08. | Medicus Pharma erzielt Fortschritte bei Hautkrebsmittel vor FDA-Gespräch | 3 | Investing.com Deutsch | ||
| 21.08. | Medicus Pharma advances skin cancer treatment as FDA meeting approaches | 1 | Investing.com | ||
| 21.08. | Medicus Pharma Ltd. Provides Update on Doxorubicin Containing Novel Microneedle Array (D-MNA) Clinical Development Program for the Treatment of Basal Cell Carcinoma (BCC) of the Skin and Reports Second Quarter 2025 Financial Highlights | 246 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - August 21, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development... ► Artikel lesen | |
| 11.08. | Medicus Pharma Ltd. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 04.08. | Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines | 304 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - August 4, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Helix Nanotechnologies Inc. ("HelixNano"), a Boston-based biotech company focused... ► Artikel lesen | |
| 04.08. | Medicus Pharma Ltd. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.07. | Medicus Pharma Ltd. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.07. | Medicus Pharma Ltd. Announces Voting Results Following the Annual and Special Meeting of Shareholders | 379 | Newsfile | Philadelphia, Pennsylvania--(Newsfile Corp. - July 23, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company") is pleased to announce the voting results of the Company's annual and... ► Artikel lesen |
1 2 3 4 Weiter >>
77 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 22,005 | -0,34 % | KI befügelt Krebsforschung: Die nächsten 150 % Gewinner sind Bayer, Vidac Pharma und Pfizer | Die Börse läuft und läuft! Zur Tech- und Rüstungshausse kann in den letzten Tagen sogar der BioTech-Sektor aufholen, denn jüngste Meldungen im Bereich Krebsforschung bringen die Branche erneut ins Rampenlicht.... ► Artikel lesen | |
| GILEAD SCIENCES | 101,40 | -0,28 % | Breaking Down Gilead Sciences: 6 Analysts Share Their Views | ||
| VERTEX PHARMACEUTICALS | 363,70 | +0,37 % | What Makes Vertex Pharmaceuticals (VRTX) an Investment Bet? | ||
| EYEPOINT PHARMACEUTICALS | 11,215 | -6,07 % | EyePoint stock rating reiterated at Outperform by Mizuho amid competitor review | ||
| ASTRIA THERAPEUTICS | 6,550 | -9,66 % | Astria Therapeutics, Inc.: Astria Therapeutics rekrutiert nun HAE-Patienten in der Europäischen Union für die Phase-3-Studie ALPHA-ORBIT | Astria Therapeutics, Inc. (Nasdaq:ATXS), ein Biopharma-Unternehmen mit Schwerpunkt auf der Entwicklung lebensverändernder Therapien für allergische und immunologische Erkrankungen, gab heute bekannt... ► Artikel lesen | |
| OPKO HEALTH | 1,309 | -1,49 % | OPKO Health, Inc.: OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting | MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 156,00 | -1,89 % | Ligand Pharmaceuticals: Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance | Second quarter performance driven by strong portfolio royalty revenue growth of 57% 2025 full year revenue guidance increased to $200 million - $225 million (previously $180 million - $200 million)... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 118,10 | -0,34 % | Jazz Pharma: FDA Approves Zepzelca + Tecentriq Combo For First-Line Maintenance In ES-SCLC Patients | WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ) announced that it has received U.S. FDA approval for Zepzelca (lurbinectedin) in combination with either atezolizumab (Tecentriq) or atezolizumab... ► Artikel lesen | |
| UNITED THERAPEUTICS | 388,00 | +0,47 % | TD Cowen bestätigt Kaufempfehlung für United Therapeutics und verweist auf IPF-Potenzial | ||
| ROYALTY PHARMA | 30,910 | -0,26 % | Royalty Pharma Expects At Least Mid-teens Average Annual Total Shareholder Return Over 2025-2030. | WASHINGTON (dpa-AFX) - Royalty Pharma plc (RPRX) Thursday said it will host an Investor Day today, where senior executives will provide updates on the company's strategies aimed at driving shareholder... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 17,695 | +0,88 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE (amifampridine) Patent Litigation with Lupin Pharmaceuticals | CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 47,550 | -0,04 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | PALO ALTO, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today... ► Artikel lesen | |
| TG THERAPEUTICS | 30,675 | -0,24 % | H.C. Wainwright initiates TG Therapeutics stock with Buy rating on MS drug growth | ||
| AVADEL PHARMACEUTICALS | 12,300 | 0,00 % | Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Celebrates Five Years of Driving Growth in Sleep Research Funding | A Media Snippet accompanying this announcement is available by clicking on this link. DUBLIN, Sept. 16, 2025 (GLOBE NEWSWIRE) -- The American Academy of Sleep Medicine Foundation (AASM Foundation)... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 12,600 | +8,62 % | Corbus Pharmaceuticals Holdings, Inc.: FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma | Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted by FDA for CRB-701 NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus... ► Artikel lesen |
MEDICUS PHARMA LTD gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +2,89 % bei einem Aktienkurs von 2,490 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.